SAN FRANCISCO, Nov. 5, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that Co-Founder and Chief Executive
Officer (CEO) Matthew R. Patterson
has been appointed Chairman of the Board of Directors. The
Board of Directors also appointed Louis G.
Lange, M.D., Ph.D. as Lead Independent Director. Mr.
Patterson and Dr. Lange have held board member roles since 2012 and
2015, respectively.
"It is a great privilege for me to serve our company as Chairman
of the Board of Directors," stated Matthew
R. Patterson, Chairman and CEO. "Audentes is at an
exciting inflection point, and I look forward to working closely
with the board and management team to deliver on important
milestones that advance our mission of developing innovative gene
therapy products for patients living with serious, life-threatening
rare diseases."
Mr. Patterson continued, "I am also pleased to announce the
appointment of Dr. Lange to the position of Lead Independent
Director. Lou is a recognized leader in the biotechnology
industry who brings a unique and valued perspective to our
organization. We're fortunate to benefit from Lou's deep
experience gained over a successful career as a physician and
founder and CEO of innovative public biotechnology companies, and I
look forward to partnering with him in the leadership of our
board."
Mr. Patterson has more than 25 years of experience in the
research, development, and commercialization of innovative
treatments for rare diseases and has held positions of senior
management in both private and public biotechnology
companies. Previously Mr. Patterson worked for Genzyme
Corporation, BioMarin Pharmaceutical, and Amicus
Therapeutics. Prior to Audentes he was an
Entrepreneur-In-Residence with OrbiMed, one of the world's largest
healthcare dedicated investment firms. Mr. Patterson
currently serves as Chairman of the Alliance for Regenerative
Medicine (ARM), the international advocacy organization
representing the gene and cell therapy and broader regenerative
medicine sector. He is a member of the Board of Directors for
Homology Medicines, Inc., Modis Therapeutics, Inc., and Gilda's
Club of New York City, which
provides support for people living with cancer. Mr. Patterson
received his Bachelor's degree in Biochemistry from Bowdoin College.
Dr. Lange was the founder of CV Therapeutics, and as the
Chairman, CEO, and Chief Scientific Officer, led the company
through an IPO, the approval of two first-in-class cardiovascular
drugs, RANEXA® and LEXISCAN®, and the sale of the company to Gilead
Sciences, Inc. Prior to joining industry, Dr. Lange spent 22
years in academic medicine at Harvard
and Washington University, where he
served as Chief of Cardiology and Professor of Medicine at Jewish
Hospital and was one of the first academicians in molecular
cardiology. Dr. Lange is currently a General Partner at Asset
Management Ventures, serves as a senior advisor to Gilead Sciences,
Inc., and has served on numerous other public and private boards in
both the non-profit and for-profit sectors. Dr. Lange holds a
Doctorate degree in Biochemistry from Harvard
University and a Medical Doctor degree from Harvard Medical School. He earned a
Bachelor's degree from the University of
Rochester.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of X-linked Myotubular Myopathy
(XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to: anticipated clinical
milestones, potential pipeline expansion, the timing and nature of
clinical development and regulatory activities. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. Although the
company believes that the expectations reflected in such
forward-looking statements are reasonable, the company cannot
guarantee future events, results, actions, levels of activity,
performance or achievements, and the timing and results of
biotechnology development and potential regulatory approval is
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause the company's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, the company's ability to fund development
activities and achieve development goals, establish and scale-up
manufacturing processes that comply with regulatory requirements,
protect intellectual property and other risks and
uncertainties described under the heading "Risk Factors" in
documents the company files from time to time with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and the
company undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-board-of-directors-appoints-co-founder-and-chief-executive-officer-matthew-r-patterson-as-chairman-300742804.html
SOURCE Audentes Therapeutics, Inc.